WeCITEProve a therapeutic capability before disclosing the compound or method.
A pharmaceutical company can establish that valuable knowledge exists, demonstrate ownership and let an authorized counterpart evaluate relevance before controlled diligence begins.
Confidential formulation capabilityCompound + method · Owner-controlledEvidence verified · disclosure not required
Built for industries where revealing first destroys the advantage.
PHARMA / KNOWLEDGE DEPLOYMENTOWNER-CONTROLLED
ASSET / PHARMA-R&D-021
Controlled-release formulation capability
Corporate R&D asset · formulation and method remain concealed
VISIBLE CAPABILITY SIGNALS
DELIVERY / CONTROLLEDROUTE / ORALEVIDENCE / VALIDATEDRIGHTS / LICENSABLE
01Deploy privatelyCorporate R&D → governed capability signal
02ComparePatents, papers + permissioned knowledge
03CreateCombine internal + external capabilities
04Buy or sellLicense knowledge in or out under company policy
Zero-Knowledge Discovery (ZKD) is WeCITE's privacy-preserving discovery protocol: protected knowledge can be searched, matched and evaluated without disclosing the underlying confidential content. WeCITE compares a privacy-preserving semantic representation with public patents and papers, or with other permissioned representations, returning signals of relevance, proximity and rights without revealing the original assets.